Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06779136
PHASE3

Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis

Sponsor: Shanghai Mabgeek Biotech.Co.Ltd

View on ClinicalTrials.gov

Summary

A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.

Official title: A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of a Humanized MG-K10 Mab Injection in Subjects With Prurigo Nodularis.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2025-02-26

Completion Date

2026-11

Last Updated

2025-04-18

Healthy Volunteers

No

Interventions

DRUG

Placebo

Every four weeks, subcutaneous injection,Switch to MG-K10 treatment after 24 weeks of administration

Locations (1)

Peking University People's Hospital, Beijing,

Beijing, Bejing, China